Catherine Stanton

Title: Catherine Stanton: Innovator in Health and Metabolic Research

Introduction

Catherine Stanton is a prominent inventor based in Fermoy, Ireland, known for her significant contributions to health and metabolic research. With a total of five patents to her name, she has made remarkable strides in the field of microbiology and its applications in health improvement.

Latest Patents

Stanton's latest patents include groundbreaking work on GABA-producing culturable bacteria, which are utilized for improving health. One notable composition is designed for regulating or treating metabolic diseases, featuring an isolated bacteria (DPC6108) that was deposited with the National Collection of Industrial and Marine Bacteria Limited (NCIMB) on November 28, 2011, and assigned the accession number NCIMB 41903. Additionally, she has developed a strain known as APC 1472, which has demonstrated weight-lowering effects in vivo. This strain induces satiety by decreasing the internalization of the Ghrelin receptor, leading to reduced activity. Furthermore, it has shown improvements in glucose tolerance and decreased insulin plasma levels in mice, indicating its potential in preventing and treating Type II diabetes, particularly in obese individuals.

Career Highlights

Throughout her career, Catherine Stanton has worked with esteemed institutions such as University College Cork and Teagasc, the Agriculture and Food Development Authority. Her research has focused on the intersection of microbiology and health, leading to innovative solutions for metabolic disorders.

Collaborations

Stanton has collaborated with notable colleagues, including Paul Ross and Colin Hill, who have contributed to her research endeavors and advancements in the field.

Conclusion

Catherine Stanton's work exemplifies the impact of innovative research on health and metabolic diseases. Her patents and collaborations highlight her commitment to improving health outcomes through scientific discovery.